Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wanda Phipatanakul

Allergy & Immunology Boston, MA Medical Doctor

NPI 1952409005 CMS profile 134187

300 Longwood Ave, Boston, MA 02115

Open in the dashboard

General payments

$678,624

566 records reported · program years 2019–2025

Research payments

$23,750

Paid to them · 60 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,492,393 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Wanda Phipatanakul of Boston, MA is reported in the CMS Open Payments database as having received $678,624 across 566 general payments and $23,750 in research payments paid to them. Separately, studies naming them as principal investigator received $2,492,393 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $149,059 104
2025 Research $7,500 21
2024 General $97,921 75
2024 Research $1,250 1
2023 General $182,241 151
2023 Research $4,500 10
2022 General $104,396 116
2022 Research $7,500 20
2021 General $56,677 31
2021 Research $3,000 8
2020 General $7,121 8
2019 General $81,208 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wanda Phipatanakul
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Wanda Phipatanakul were reported at $149,059. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Wanda Phipatanakul Allergy & Immunology median Middle half National median
2019 $81,208 $594 $163–$1,512 $163
2020 $7,121 $426 $106–$1,233 $114
2021 $56,677 $638 $157–$1,708 $132
2022 $104,396 $790 $205–$1,961 $149
2023 $182,241 $852 $220–$2,147 $160
2024 $97,921 $865 $203–$2,267 $164
2025 $149,059 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $221,639 113 payments
  2. Regeneron Healthcare Solutions, Inc. $166,230 198 payments
  3. Genentech USA, Inc. $73,405 65 payments
  4. AstraZeneca Pharmaceuticals LP $70,261 60 payments
  5. GlaxoSmithKline, LLC. $41,160 48 payments
  6. Regeneron Pharmaceuticals, Inc. $21,795 7 payments
  7. Novartis Pharmaceuticals Corporation $16,072 14 payments
  8. Merck KGaA $13,849 2 payments
  9. ARS Pharmaceuticals Operations, Inc. $12,162 10 payments
  10. Chiesi USA, Inc. $8,466 4 payments
  11. Other $33,583 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $374,624 131 payments
  2. Consulting Fee $174,912 52 payments
  3. Travel and Lodging $112,584 231 payments
  4. Food and Beverage $9,504 149 payments
  5. Grant $6,000 2 payments
  6. Honoraria $1,000 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $135,427 67 payments
  2. DUPIXENT Inflammation And Immunology $114,926 127 payments
  3. Xolair $58,081 50 payments
  4. TEZSPIRE $52,089 42 payments
  5. NUCALA Immunology $27,261 38 payments
  6. DUPIXENT Immunology And Inflammation $26,848 26 payments
  7. AIRSUPRA $13,712 12 payments
  8. NEFFY $12,162 10 payments
  9. NUCALA Respiratory $8,500 7 payments
  10. RINVOQ $6,331 14 payments
  11. Other $43,708 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $23,750 60 payments

Records

626 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record